CORRELATION OF SERUM ANTI-MULLERIAN HORMONE LEVELS WITH MATURE OOCYTE COUNT AND BLASTOCYST FORMATION IN IN VITRO FERTILIZATION CYCLES

Do Ngoc Lan1, Trinh The Son1, , Doan Thi Hang1, Nguyen Minh Phuong1
1 Military Institute of Clinical Embryology and Histology, Vietnam Military Medical University

Nội dung chính của bài viết

Tóm tắt

Objectives: To evaluate the correlation between serum anti-Mullerian hormone (AMH) levels and the total number of oocytes, the proportion of mature oocytes, and the proportion of good-quality blastocysts. Methods: A retrospective observational study was conducted on 435 women (18 - 45 years of age) undergoing in vitro fertilization (IVF) at the Military Institute of Clinical Embryology and Histology from June 2023 to December 2024. Patients were divided into four groups: Women < 35 years old with low AMH (< 1.2 ng/mL, n = 60) and normal AMH (≥ 1.2 ng/mL, n = 119), and women ≥ 35 years old with low AMH (n = 96) and normal AMH (n = 160). Results: The antral follicles count (AFC) was significantly higher in the normal AMH group compared to the low AMH group (16.33 ± 6.24 vs. 8.83 ± 4.26, p < 0.001) among women < 35 years, and (12.92 ± 6.29 vs. 7.26 ± 3.46, p < 0.001) among women ≥ 35 years. The median number of mature oocytes (MII) was higher in the normal AMH group (8 vs. 4 oocytes) in women < 35 years, and (6 vs. 3 oocytes) in women ≥ 35 years. The median number of usable blastocysts differed significantly (p < 0.001) between low and normal AMH groups: 2 vs. 4 blastocysts in women < 35 years, and 1 vs. 3 blastocysts in women ≥ 35 years. However, the proportions of mature oocytes and blastocyst formation showed no significant differences across the groups. Conclusion: Serum AMH levels were positively correlated with the number of mature oocytes and usable blastocysts, but were not significantly associated with oocyte or blastocyst quality in IVF cycles. 

Chi tiết bài viết

Tài liệu tham khảo

1. Weenen, C, et al. Anti‐Müllerian hormone expression pattern in the human ovary: Potential implications for initial and cyclic follicle recruitment. Molecular Human Reproduction. 2004; 10(2):77-83.
2. La Marca, A, et al. Serum anti-Mullerian hormone throughout the human menstrual cycle. Human Reproduction. 2006; 21(12):3103-3107.
3. Heidary, Z, et al. The association of AMH level with the number and quality of oocytes in women undergoing IVF/ICSI: A single-center study. Journal of Reproduction & Infertility. 2024; 25(1):38.
4. Steiner, AZ and AMZ Jukic. Impact of female age and nulligravidity on fecundity in an older reproductive age cohort. Fertility and sterility. 2016; 105(6):1584-1588. e1.
5. Harris, I, et al. Determining the optimal cut-off value for antimullerian hormone in ovarian reserve testing. Fertility and Sterility. 2011; 96(3):S193.
6. Munné, S, et al. Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: A multicenter randomized clinical trial. Fertility and Sterility. 2019; 112(6):1071-1079. e7.
7. Dai, X, et al. AMH has no role in predicting oocyte quality in women with advanced age undergoing IVF/ICSI cycles. Scientific reports. 2020; 10(1):19750.